Moving on to greener pastures.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The shares are not necessarily going to be issued.
These will be treasury shares which the company can use to use for a buy in or a buyout situation.
They could make a Another special offering just like they did in October for $61 million.
Having been engaged with this company since April 2014 my view is this is a good and bullish move by the board of directors/management team
You can look at several other companies that have done similar things in the last five years and they have all worked out well. One of those companies is named Exact Sciences.
They started TV advertising March of 2016.
The upward trajectory has been almost straight up since they started advertising.
MannKind Will follow the same pathway towards rising PPS. Many other Pharma companies have seen this same progress after begetting television advertising.
I can support them adding the additional shares as the company needs the flexibility to create international partnerships from a Pharma that wants to buy into selling
Afrezza somewhere else in the world.
Will we break $400. By thanksgiving. Been in intuitive since Feb 2010. Great stock to own
So will the intuitive BO offer come this week or next week.
My guess is that they are not nervous about TRXC getting a bit of market share as they could smash them like a bug. Heck they could make an offer $20.00 and buy the company and that would be the end of your $300.00 sell order.
Glad they had good attendance and the doctors liked what they saw. But again its only the beginning and one sale does not scare Intuitive about TRXC...
They can fix that with sales of their product. But that will take time and serious marketing talent.
Evidently common sense conversation about MannKind is not an acceptable posting.
I know one thing I like my intuitive stock. It hit $392.00 today which is 1,172.00 pre split. So if TransEnterix gets to $900.00 in the future then I will be rich.
Titan will never make it unless they get purchased by a larger company. They have missed the boat on coming to market.
TransEnterix made the cut. They got FDA approved. They now have a US sale. They are on their way to being interesting to a larger company like J & J or somebody else operating in the space.
TransEnterix need capital and that will come easier since they have FDA approval and a first sale. My belief is they need to get a sales & marketing partner to help them build sales while they focus on the product.
Always nice to read a great story from a Afrezza user. Riva Greenberg.
The story about Afrezza is being told almost every day and it’s becoming very viral. No other Insulin begins working in 12 minutes. That is ultra-fast. The new label will be the ultimate game changer.
Afrezza does it for me first time out
NOVEMBER 12, 2017
RIVA GREENBERG
https://diabetesstories.com/2017/11/12/afrezza-does-it-for-me-first-time-out/
I know a lot of type 1s have waxed poetic over the amazing effects of Afrezza-particularly it’s quick onset and just as quick exit from the body. That always appealed to me, but I couldn’t fathom how I could use it when the smallest dose it comes in, in its little colored blister packs as seen above, is 4 units. Eating low carb I rarely take more than 1 unit of rapid acting insulin for a meal.
That said, when I went to my endo last month something made me ask him if he had any samples he could give me so I could just try it. And, with unusual foresight, I packed it last night into my luggage for a two month trip I have just embarked upon overseas. While my blood sugar is pretty predictable when I’m home sticking to my routine, it’s all but that when I travel and have little influence over what I eat, jet lag, what my body’s biorhythms are doing, etc, etc…
So right out of the box, or I guess I should say gate, landing in Amsterdam at 9 AM Dutch time, 3 AM NYC time, being met by the husband, we sat for a cappuccino. Boom! My blood sugar began climbing from 102 to 194. I got out my insulin and began dosing single units until I’d taken 5. I daren’t do more. Even though my blood sugar was 264 and did’t seem to be budging, I knew eventually it would. And that the crux, it takes so dang long to come down. Two hours later it was slowly sliding back down.
Now 1:30 PM Dutch time, 7:30 AM NYC time, we went for lunch. I had mushroom soup and a stir fry with just vegetables and beef. I didn’t take any insulin because I figured I had enough on board to cover this meal. I didn’t. Boom! It started climbing again. Now, at 200 again, I took one unit of insulin and we walked around the corner back to our hotel so I could try Afrezza. No way I wanted a repeat of the morning’s runaway blood sugar train and hours to come back down.
A short search through my knapsack revealed the little box. A quick video on YouTube showed me how to load the inhaler and take a drag. Then I put Pinkie’s (Dexcom CGM), receiver and my iPhone both, in my pockets, and said a little prayer. I had no idea if I’d inhaled properly and would see results and I was scared if I did, how low would I go?
The darn stuff works! Within 15 minutes my climb reversed and I was coming down. Within 45 minutes I was at 120, In an hour and 15 minutes Pinkie was telling me I was at 84 with the arrow going straight down, then 70, arrow still straight down, then 55. I felt fine, but who knew. Checking on my meter I was 86. I remembered when your blood sugar’s going up or down rapidly, Pinkie needs time to catch up and straighten herself out from the roller coaster fragmentation. I took 2 glucose tablets to create some cushion. Within 2.5 hours I was 105 and I felt Afrezza had left my body
If I hadn’t already taken the 1 unit for lunch, and just taken the Afrezza, I think it would have worked just great. As I’ve been told, 4 units of Afrezza, the smallest dose, works like 2 units of rapid acting insulin in the body. I can definitely see the value of heading off runaway highs and getting back in target range much faster than with injected insulin. That is always my frustration, how slow insulin is to get working.
While I can’t use Afrezza often because I am insulin sensitive and do eat a low carb diet, I’m going to want to have it around when what’s around me is not my norm.
So, listen up everyone in Copenhagen, London, Abu Dhabi, Singapore, Sydney, San Francisco and Portland where I’ll be coming through, Afrezza is in my backpack and if you see me taking a drag I’ll probably have a smile on my face and rest assured it’ll be the insulin I’m toking on, not a souvenir from Amsterdam .
Not a lot of value shorting a penny stock
Company is bankrupt. Based on the third-quarter figures. This will be down to listen .104 the end of the year
I listen to their conference call and believe that they are moving in the right direction. Todd Pope seems to be a great CEO.
I personally believe that they need to find a partner to assist them in their sales and marketing effort. Very similar to the partnership that Mazor robotics made with Medtronics.
You can put a fork in Titan As they are about bankrupt it will never get there robotic equipment to market.
The confidence that Todd Pope had during the Q&A shows that they are on the right track.
The after hours trading also showed there were buyers for over 800,000 shares.
Based on what will it go up to 1.35
Ha ha ha Long as the Day has 24 hours.
Just ask Mazor who continues to thrive with their partner Medtronic.
Having a FDA approved product and partner is key to TITAN success and survival.
Today Titan risks running out of time and capital and being a product either left behind or completed by Another company who picks up the company on the cheap or bankruptcy. Better hope for a white knight to survive.
Maybe Mazor with their new found cash will buy Titan.
Masa Son is a crazy man. Not sure what is next. I think he is in over his head. They say Sprint if valuable due to 5G investment. I guess we will see if that is the case.
In the history of sprint they have executed very poorly and that goes back to Bill Esrey and Ron LeMay who plundered the company while they stole hundred of million in their own pockets.
Sprint has lost their way since about 1995. Very sad. The Nextel deal again hurt the company.
Sprint needs to be sold to Amazon who needs a 2nd HQ and KC would be perfect for it. The Sprint HQ is 20 building’s on 200 acres about 75% under utilized. Leased out to others.
This would be a perfect pick up for Amazon. Get Sprint and a 2nd HQ in the center of the country.
No Monday surprise and buyout share price is stock exchange. So the value is minimal. Probably $6.50 where it is sitting.
Hopefully another deal comes forward like with Charter and gets this up to 8.5 so I can exit.
My due diligence says until this company gets a sales and marketing partner to help move the product the PPS will not grow
Better coffee than Five bucks coffee.
Companies like intuitive are few and far between. Mazor might just be another one that really makes it big. But they needed help and Medtronic provided that help with Sales & Marketing and a Buy in.
But there are many other small companies that will not make it and run out of capital. I have invested in them and have lost.
Maybe ISRG will take a run at buying into or buying out some of the others that are just breaking into the space but for every ten that try to make it only a couple of them due like ISRG.
The others will name make it to the finish line and run out of cash trying to get FDA approval.
Amazing company. Shareholder since 2010 and have to say that I wish that I had more shares. Pre-split is $1,185.00 today. Amazing.
I don't think that Masa Son has a clue. The company needs new leadership and the TMUS deal would be best. At least the folks in the Sprint HQ in KC would have some direction.
This afternoon's KC Business Journal
On-again, off-again Sprint/T-Mobile deal perpetuates jobs uncertainty https://www.bizjournals.com/kansascity/news/2017/11/03/sprint-tmobile-merger-uncertainty-jobs.html via @KCBizjournal
There is no clear message or direction for Sprint employees except to hold on and see what happens.
That is False information. Fly on the way did not post that. I would doubt there is a buyout pending by ISRG.
here is a link and the last item was the Stifel analyst.
https://thefly.com/news.php?symbol=TRXC
TransEnterix analyst commentary at Stifel »TransEnterix price target…TransEnterix price target raised to $4 from $3.75 at Stifel. Stifel analyst Rick Wise spoke with a number of leading surgeons at the 2017 ACS meeting last week regarding TransEnterix's robotic surgical system, Senhance. The analyst said surgeon interest in Senhance is clearly high and reaction was positive to Senhance's differentiated feature set and economics, which bode well for adoption, utilization, and 2018 outlook. Wise reiterated his Buy rating on TransEnterix and raised his price target to $4 from $3.75.
Read more at:
https://thefly.com/landingPageNews.php?id=2631527
That would be a good deal as the folks on the Titan board says that TRXC will never make it. Funny how they have very thin skin when that company has tried for a long time to get traction and has failed.
TRXC needs a company like Intuitive to buy in or buy out as TRXC needs the sales & Marketing clout that it would bring to place the product. If not Intuitive then perhaps a company like J & J.
When was ACS? How are you sure there is news today after the bell?
You first have to have capital to get commercialized before you can compete with any other players in the market place. Oh and you also have to get FDA approval.
Seems you can fantasize about taking on ISRG but they are crushing the market with sales. Pre split they are $1,155.00 per share or = to 3,208 shares of TITXF.
The key to get FDA approval. There is no upside until that point.
This is not good news for Corindus
https://www.nytimes.com/2017/11/02/health/heart-disease-stents.html
‘Unbelievable’: Heart Stents Fail to Ease Chest Pain
A procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday. …
10/27/2017
Symphony data week ending 10/27/17:
NRx = 267
TRx = 446
$TRx = $416,000
This does not even reflect the new label yet. You won’t see those changes for another couple of months. Perhaps by April 2017.
Read more: http://mnkd.proboards.com/thread/1742/afrezza-script-counts-symphony-data#ixzz4xMtfynml
I talked about get Titan thru approval and what it takes. It will take a Partner. Period end of game if they don’t have somebody with the sales and marketing ability. The sales cycle is long and Titan can hardly pay their light bills much less go to conventions and to market sport.
It’s alright to not understand what it takes after approval. That is why the company is trading at .367 one better hope they find that angel company like many others have to buy into or buy it out.
Last posting by me. I wanted to try and understand where Titan was in relationship to when I dumped the shares after a good lose back in 2016.
But Mazor has finally made it big and gaining traction with sales and a partner. Both of these items allow more R & D investment for products in different Robotic modalities.
Titan needs to get that approval to get to the next step of production and finally sales. It takes a lot of capital. One step forward and five steps backwards.
Buy out would be a blessing at this time with real sales and marketing effort they need to BO or a Buy in by a good partner like MDT did in the last 18 months with Mazor.
Mazor struggled for about 15 years but made it big in the last 18 month with most of being in 2017
If you read my messages I did not pick one over the other. I would not do that. I like investing in a few speculative stocks while my other long-term holdings are doing great
That is not my point at all. As I said to compare and contrast other people operating in that space. But so be it I will stop posting anything on this board.
One needs to see the overall surgical robotic market. It’s huge and has opportunity for all the players. With the players need to have capitalization, and sales and marketing.
Only to compare and contrast how the various companies in the surgical robotics space are doing.
Not to draw attention to any one of them specifically.
I was invested in titan for two years and did not do very well.
So I came back to look and see if it was time to invest again.
TRXC was a stock I probably should not have bought it I was seduced by the fact they have a lot of potential ahead of it.
Just like Titan they hurry development stage company. And have no sales.
I also own intuitive surgical. Have been in that stock since 2010. Smiling all the way to the bank.
So my motivation is to try to find a few speculative companies that have potential for future PPS growth
The great thing that MaZoe has going for it is they do not have any exclusively with Medtronic on any procedures other than spinal procedures.
So Mazor can develop partner with others for different types of procedures. That is a big spectrum various modalities in surgery.
Their agreement only allows MDT at this time to own 15% of their shares to prevent a hostile takeover by. Medtronic.
This is a great sales and marketing partnership.
Whether your Titan or TransEnterx you need to have a sales and marketing partner it makes life easier to focus on the development of the product and let others do with the sales side.
you’re wrong. Mazor has a very robust system and they are going to clean up and be more like intuitive surgical. Let’s watch and see what unfolds the next 36 months with Mazor.
Then let’s see where Titan is in 36 months ??
My concern is is they don’t have enough people or capital to properly commercialize . They need to have a partner who can help them. I hope that is in the plans. I don’t see this as a long-term holding. It will take 3 to 5 years or more to gain critical mass if they are successful in selling their product
You cannot make stories like this up. Actually users love the product
Actual user.
I was on an inhalable clinical trial with Novo and loved it. But they pulled the product. I am now on Afrezza, after taking 5-6 injections a day. It has only been two months, but my body is feeling better. I am taking one injection a day, Tresiba, and multiple inhalations. Once you get used to taking it, you will find it much better than multiple injections.
Actual user.
Afrezza is amazing! How quickly it works and then gets out of your system makes such a huge difference! I was also diagnosed in my 20s - 27 years ago, and I have done pens, insulin pump, and now Afrezza. This is by far the best for me! I also use a Dexcom CGM and the combination of both of those things has gotten my A1C down to 5.7 - something I thought would never be possible! There is definitely an adjustment period because the Afrezza works so differently, but it's great to get rid of that pump - not to mention the improved A1C!
Actual user.
I echo what Don said above. Life changing. Was on a pump for 22 years (I’m 43). And never have I been so excited about handling my blood sugar. Like those above, feel free to PM me if you want. We can even talk over the phone if you’d like.
Actual user.
I love the Afrezza. I ususally take the 4 uits, unless i cheat then i take the 8 units, 3 times a day. It's really fast acting. The only downfall is sometimes getting choked up on the powder. Otherwise, Highly Recommend!!
Actual user
Life changing. Fast in and fast out. Been on it for 6 months - freedom from carb counting, freedom to eat more of the foods I like, and my A1C is at all time low. Feel free to PM me for more info or more specific questions.
$TRXC $JNJ might want a piece since $MDT tied up $MZOR
fortunately I am in under $3.00 and will dump it if it gets back to that number.